Four ways to increase rare disease drug development success
There are more than 7,000 identified rare diseases today, 71.9% of which are genetic. And only around 5% of rare diseases have treatments. Development is complex and presents specific challenges. For example, many rare disease patients are children, since nearly 70% of rare diseases are exclusively pediatric-onset. The patient pool is often very limited for any one disease, and patients are often geographically dispersed, highlighting the importance of selecting a development partner with strong patient recruitment and global operational capabilities.
In this playbook, Parexel shares insights on maximizing the chances of success in rare disease drug development, providing our perspectives on four of the most significant challenges:
- Easing trial burdens on sites, and enhancing the clinical staff experience
- Ensuring that pediatric trials are ethical and feasible for patients and families
- Getting to market faster and stronger with natural history studies and real-world evidence
- Learning from past successes and failures in orphan indications
We hope you find these articles helpful on your journey.
Related Insights
Report
Fit-for-purpose outsourcing models: Adapting to a world of untapped innovation and emerging risks
Jun 20, 2025
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Article
Part Two: The Emergence of Chinese MedTech on the Global Stage
Sep 7, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Blog
Taking a Proactive, Preventive Approach to Data Privacy in Clinical Documentation
Sep 26, 2022
Video
A Life in a Day
Jul 28, 2022
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022
Related Insights
Report
Fit-for-purpose outsourcing models: Adapting to a world of untapped innovation and emerging risks
Jun 20, 2025
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Article
Part Two: The Emergence of Chinese MedTech on the Global Stage
Sep 7, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Blog
Taking a Proactive, Preventive Approach to Data Privacy in Clinical Documentation
Sep 26, 2022
Video
A Life in a Day
Jul 28, 2022
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022